Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2019 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor

First of Several Post-hoc Analyses Planned Using HOPE Study Clinical Data Findings Presented in Poster Session at 13th Annual Academy for Sickle Cell and Thalassemia Conference SOUTH SAN FRANCISCO,...
October 07, 2019 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ: GBT) today announced that on October 1, 2019, the compensation committee of GBT’s board...
October 02, 2019 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to its sickle cell disease (SCD)...
October 01, 2019 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT to Host Analyst & Investor Day on October 8 in New York

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ: GBT) today announced that it will host an Analyst & Investor Day to provide an...
September 25, 2019 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces Participation at the 2019 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Cantor Global Healthcare...
September 05, 2019 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease

Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements...
September 04, 2019 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on September 1, 2019, the compensation committee of GBT’s...
September 03, 2019 16:05 ET | Source: Global Blood Therapeutics, Inc.

GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Morgan Stanley Global Healthcare...
September 03, 2019 08:00 ET | Source: Global Blood Therapeutics, Inc.

GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness...
August 07, 2019 16:05 ET | Source: Global Blood Therapeutics, Inc.

GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the second...